

Yale Eye Center Clinical Conference Series

"Gene Therapy and Etinal Regeneration in LCA5-Associated Leber Congenital Amaurosis"

Friday, January 24, 2020


7: 00 am - 8:15 am

Temple Medical Center Conference Room Lower Level, 60 Temple Street

> Course Director: Ron A. Adelman, MD, MPH, MBA

There is no corporate support for this activity.

This course will fulfill the licensure requirement set forth by the State of Connecticut.



Katherine Uyhazi, MD, PhD
Instructor of Ophthalmology
University of Pennsylvania

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Eye care professionals.

NEEDS ASSESSMENT

Understanding advances in retinal gene therapy. Announcing new clinical trial enrollment opportunities. Bridging the gap between basic science research and drug development. Understanding animal models of human disease

LEARNING OBJECTIVES

At the conclusion of the conference, meeting participants will be able to:

- Understand how animal models reflect human blinding diseases.
- Understand the indications and limitations of gene therapy.
- Understand the potential of cellbased therapies for retinal regeneration.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Speaker: Katherine Uyhazi, MD, PhD –

Director: Ron A. Adelman, MD, MPH, MBA – NONE

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.